Literature DB >> 8947921

Sigma binding in a human neuroblastoma cell line.

J Ryan-Moro1, C C Chien, K M Standifer, G W Pasternak.   

Abstract

Behaviorally, sigma1 agents modulate opioid analgesia. To examine possible mechanisms responsible for these interactions, we have identified a cell line containing both sigma1 and opioid receptors. [3H](+)-pentazocine binding in BE(2)-C human neuroblastoma cells is high affinity (KD 3.4 +/- 0.7 nM) and high density (Bmax 2.98 +/- 0.14 pmol/mg protein). Competition studies reveal a selectivity profile similar to that of sigma1 sites in guinea pig brain. (+)-Pentazocine has no effect upon either basal or forskolin-stimulated cyclase in the BE(2)-C cells, but cAMP accumulation is inhibited by the morphine, DPDPE and naloxone benzoylhydrazone. (+)-Pentazocine at concentrations as high as 10 microM does not affect this opioid effect, implying that sigma1/opioid interactions are not mediated at the level of the cell. This suggest that their behavioral interactions result from interacting neural circuits. Although (+)-pentazocine is without effect in the cyclase system, it does block carbachol-stimulated phosphoinositol turnover (IC50 6.5 +/- 1.14 microM). The specificity of the effect is confirmed by the ability of haloperidol (1 microM) to shift the IC50 value of (+)-pentazocine 2-fold to the right.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947921     DOI: 10.1007/bf02532372

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  41 in total

1.  Opioid agonists binding and responses in SH-SY5Y cells.

Authors:  E M Costa; B B Hoffmann; G H Loew
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

2.  Coupling of opiate receptors to adenylate cyclase: requirement for Na+ and GTP.

Authors:  A J Blume; D Lichtshtein; G Boone
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

3.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

Review 4.  Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties.

Authors:  G A Weiland; P B Molinoff
Journal:  Life Sci       Date:  1981-07-27       Impact factor: 5.037

5.  Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture.

Authors:  B J Vilner; W D Bowen
Journal:  Eur J Pharmacol       Date:  1993-01-15       Impact factor: 4.432

6.  Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine.

Authors:  A L Gundlach; B L Largent; S H Snyder
Journal:  J Neurosci       Date:  1986-06       Impact factor: 6.167

7.  Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.

Authors:  V Ciccarone; B A Spengler; M B Meyers; J L Biedler; R A Ross
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

8.  Evidence for a multi-site model of the rat brain sigma receptor.

Authors:  W D Bowen; S B Hellewell; K A McGarry
Journal:  Eur J Pharmacol       Date:  1989-04-25       Impact factor: 4.432

9.  Characterization of specific binding sites for [3H]-1,3-di-o-tolyl-guanidine (DTG) in the rat glioma cell line C6-BU-1.

Authors:  A Georg; A Friedl
Journal:  Glia       Date:  1992       Impact factor: 7.452

10.  Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines.

Authors:  B J Vilner; C S John; W D Bowen
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

View more
  8 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

3.  Sequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress.

Authors:  Joel M Schrock; Christina M Spino; Charles G Longen; Stacy M Stabler; Jacqueline C Marino; Gavril W Pasternak; Felix J Kim
Journal:  Mol Pharmacol       Date:  2013-09-04       Impact factor: 4.436

4.  Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer.

Authors:  Jeffrey D Thomas; Charles G Longen; Halley M Oyer; Nan Chen; Christina M Maher; Joseph M Salvino; Blase Kania; Kelsey N Anderson; William F Ostrander; Karen E Knudsen; Felix J Kim
Journal:  Cancer Res       Date:  2017-02-24       Impact factor: 12.701

5.  Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding.

Authors:  Felix J Kim; Ivanka Kovalyshyn; Maxim Burgman; Claire Neilan; Chih-Cheng Chien; Gavril W Pasternak
Journal:  Mol Pharmacol       Date:  2010-01-20       Impact factor: 4.436

6.  Isolation and characterization of alternatively spliced variants of the mouse sigma1 receptor gene, Sigmar1.

Authors:  Ling Pan; David A Pasternak; Jin Xu; Mingming Xu; Zhigang Lu; Gavril W Pasternak; Ying-Xian Pan
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

7.  Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(-)-[18F]Fluspidine in Glioblastoma.

Authors:  Magali Toussaint; Winnie Deuther-Conrad; Mathias Kranz; Steffen Fischer; Friedrich-Alexander Ludwig; Tareq A Juratli; Marianne Patt; Bernhard Wünsch; Gabriele Schackert; Osama Sabri; Peter Brust
Journal:  Molecules       Date:  2020-05-06       Impact factor: 4.411

Review 8.  Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes.

Authors:  Halley M Oyer; Christina M Sanders; Felix J Kim
Journal:  Front Pharmacol       Date:  2019-10-21       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.